From the publishers of JADPRO

DLBCL Resource Center


Welcome to the JADPRO Diffuse Large B-Cell Lymphoma Resource Center! We encourage you to take a look around at all the cutting-edge information, education, research, and other resources we’ve curated to empower your practice in this disease space. If you have any feedback or questions, please contact

Katherine L. Byar, MSN, APN, BC, BMTCN®️®️®️
Oncology/ Hematology Nurse Practitioner
Fred & Pamela Buffett Cancer Center
Nebraska Medicine
Omaha, Nebraska

News & Literature Highlights

2024 ASCO Annual Meeting Abstract

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study

2024 ASCO Annual Meeting Abstract

Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study

2024 ASCO Annual Meeting Abstract

Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6


Glofitamab plus chemotherapy meets OS end point in R/R DLBCL

CPT: Pharmacometrics & Systems Pharmacology

Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

Cancer Diagnosis & Prognosis

Clinical outcomes in patients with DLBCL treated with R-CHOP according to radiotherapy and interim PET response


Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: A systematic review and meta-analysis

Journal of Patient-Reported Outcomes

Are changes in patient-reported outcomes prognostic for diffuse large B-cell lymphoma survival? Results from the GOYA trial


Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study

EJNMMI Research

Evaluation of therapeutic effect and prognostic value of 18F-FDG PET/CT in different treatment nodes of DLBCL patients